Trial Profile

A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vapendavir (Primary)
Indications Rhinovirus infections
Focus Therapeutic Use
Acronyms CHALLENGE
Sponsors Altesa Biosciences

Most Recent Events

19 May 2026 According to Altesa BioSciences media release, data from the trial were presented at the American Thoracic Society International Conference (ATS) 2026.
19 May 2026 Results presented in the Altesa BioSciences media release.
30 Sep 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com